Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 5/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 9/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.39 |
| ▸ | CYP11A1 | P05108 | 1/20 | 0.39 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.39 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL283262 | 1.00 | CRBN (0.40) | CRBNCYP19A1CYP3A4CYP17A1CYP11A1 | |
| Bromide SCHEMBL283263 | 1.00 | CRBN (0.40) | CRBNCYP19A1CYP3A4CYP17A1CYP11A1 | |
| Bromide SCHEMBL1403663 | 0.98 | CRBN (0.39) | CRBNCYP19A1CYP3A4CYP17A1CYP11A1 | |
| Bromide SCHEMBL5506332 | 0.98 | CRBN (0.39) | CRBNCYP19A1CYP3A4CYP17A1CYP11A1 | |
| Bromide SCHEMBL5988387 | 0.98 | CRBN (0.39) | CRBNCYP19A1CYP3A4CYP17A1CYP11A1 | |
| SCHEMBL8259939 | 0.98 | CRBN (0.41) | CRBNCYP19A1CYP3A4CYP17A1CYP11A1 | |
| SCHEMBL632775 | 0.98 | CRBN (0.41) | CRBNCYP19A1CYP3A4CYP17A1CYP11A1 | |
| SCHEMBL21848668 | 0.98 | CRBN (0.41) | CRBNCYP19A1CYP3A4CYP17A1CYP11A1 | |
| Hydrochloric Acid SCHEMBL18449191 | 0.95 | CRBN (0.40) | CRBNCYP19A1CYP3A4CYP17A1CYP11A1 | |
| Hydrochloric Acid SCHEMBL18449275 | 0.95 | CRBN (0.40) | CRBNCYP19A1CYP3A4CYP17A1CYP11A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116457344-B | Low molecular weight protein degradation agent and application thereof | 凯普托尔治疗学股份有限公司 | 2026-05-12 | — | — | CN | disclosed |
| CN-119013266-A | Novel GSPT compounds and methods of use of novel compounds | 百时美施贵宝公司 | 2024-11-22 | — | — | CN | disclosed |
| US-20240294489-A1 | LOW MOLECULAR WEIGHT PROTEIN DEGRADERS AND THEIR APPLICATIONS | CAPTOR THERAPEUTICS S.A. (PL) | 2024-09-05 | — | — | US | disclosed |
| US-20240124459-A9 | PRPK INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. | 2024-04-18 | — | — | US | disclosed |
| US-20230271966-A1 | PRPK INHIBITORS | DANA FARBER CANCER INST INC (US) | 2023-08-31 | — | — | US | disclosed |
| CN-116457344-A | Low molecular weight protein degradation agent and application thereof | 凯普托尔治疗学股份有限公司 | 2023-07-18 | — | — | CN | disclosed |
| EP-4188373-A1 | LOW MOLECULAR WEIGHT PROTEIN DEGRADERS AND THEIR APPLICATIONS | Captor Therapeutics S.A. (PL) | 2023-06-07 | — | — | EP | disclosed |
| WO-2022029138-A1 | LOW MOLECULAR WEIGHT PROTEIN DEGRADERS AND THEIR APPLICATIONS | CAPTOR THERAPEUTICS S.A. (PL) | 2022-02-10 | — | — | WO | disclosed |
| WO-2022005961-A1 | PRPK INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-01-06 | — | — | WO | disclosed |
| US-20170369471-A1 | 5-SUBSTITUTED QUINAZOLINONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORP (US) | 2017-12-28 | — | — | US | disclosed |
| US-8921385-B2 | 5-substituted quinazolinone derivatives and compositions comprising and methods of using the same | CELGENE CORPORATION (US) | 2014-12-30 | — | — | US | disclosed |
| EP-2066656-B1 | 5-SUBSTITUTED QUINAZOLINONE DERIVATIVES AS ANTITUMOR AGENTS | CELGENE CORP (US) | 2012-04-25 | — | — | EP | disclosed |
| EP-2428513-A1 | 5-substituted quinazolinone derivatives as anti-cancer agents | Celgene Corporation (US) | 2012-03-14 | — | — | EP | disclosed |
| EP-2420497-A1 | 5-substituted quinazolinone derivatives as anti-cancer agents | CELGENE CORPORATION (US) | 2012-02-22 | — | — | EP | disclosed |
| EP-2420498-A1 | 5-substituted quinazolinone derivatives as anti-cancer agents | Celgene Corporation (US) | 2012-02-22 | — | — | EP | disclosed |
| US-20100093774-A1 | 5-SUBSTITUTED QUINAZOLINONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION. | 2010-04-15 | — | — | US | disclosed |
| US-7635700-B2 | e.g. 3-(5-METHYL-4-OXO-4H-QUINAZOLIN-3-YL)-PIPERIDINE-2,6-DIONE; cytokine (epidermal/fibroblast/endothelial/tumor necrosis growth factors) antagonist; antitumor, antiinflammatory agent, neurodegenerative diseases | CELGENE CORPORATION (US) | 2009-12-22 | — | — | US | disclosed |
| EP-2066656-A2 | 5-SUBSTITUTED QUINAZOLINONE DERIVATIVES AS ANTITUMOR AGENTS | CELGENE CORPORATION (US) | 2009-06-10 | — | — | EP | disclosed |
| US-20080161328-A1 | e.g. 3-(5-METHYL-4-OXO-4H-QUINAZOLIN-3-YL)-PIPERIDINE-2,6-DIONE; cytokine (epidermal/fibroblast/endothelial/tumor necrosis growth factors) antagonist; antitumor, antiinflammatory agent, neurodegenerative diseases | CELGENE CORPORATION | 2008-07-03 | — | — | US | disclosed |
| WO-2008039489-A2 | 5-SUBSTITUTED QUINAZOLINONE DERIVATIVES AS ANTITUMOR AGENTS | CELGENE CORPORATION (US) | 2008-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230271966-A1 | PRPK INHIBITORS | PRP4K, PRPS1, PRPF6 | CRBN 2384/4885CYP19A1 947/4885CYP3A4 3894/4885 |
| US-20240294489-A1 | LOW MOLECULAR WEIGHT PROTEIN DEGRADERS AND THEIR APPLICATIONS | MMP2, PSME2, PSME1 | CRBN 251/4885CYP19A1 1613/4885CYP3A4 2913/4885 |
| US-20080161328-A1 | e.g. 3-(5-METHYL-4-OXO-4H-QUINAZOLIN-3-YL)-PIPERIDINE-2,6-DIONE; cytokine (epidermal/fibroblast/endothelial/tumor necrosis growth factors) antagonist; antitumor, antiinflammatory agent, neurodegenerative diseases | FGF2, TNF, FGF1 | CRBN 2562/4885CYP19A1 2735/4885CYP3A4 1481/4885 |
| US-20100093774-A1 | 5-SUBSTITUTED QUINAZOLINONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | IL5, IL6, PGF | CRBN 3139/4885CYP19A1 236/4885CYP3A4 112/4885 |
| US-20240124459-A9 | PRPK INHIBITORS | PRP4K, PRPS1, PRPF6 | CRBN 2384/4885CYP19A1 947/4885CYP3A4 3894/4885 |
| US-20170369471-A1 | 5-SUBSTITUTED QUINAZOLINONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | IL5, IL6, PGF | CRBN 3139/4885CYP19A1 236/4885CYP3A4 112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.